Hexarelin Research Profile: GHRP Mechanism, Potency & Cortisol Considerations
Hexarelin is a potent hexapeptide GHRP with high GHS-R1a binding, cortisol and ACTH co-stimulation, and cardioprotective preclinical data in 2 animal models.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Hexarelin, the synthetic hexapeptide growth hormone secretagogue (GHS) also known by the INN name examorelin, occupies a distinctive position in the GHRP research literature: it stimulates growth hormone (GH) release more potently than either GHRP-6 or ipamorelin in direct comparisons, yet co-activates the cortisol and ACTH axes in ways that ipamorelin does not. Understanding this distinction is central to how hexarelin has been positioned in published preclinical research — both as a GH secretagogue and as a compound with cardiac-specific, GHSR-independent signaling properties.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Hexarelin (examorelin) is a hexapeptide GHS-R1a agonist that produces potent pulsatile GH release alongside cortisol and ACTH co-stimulation — a key methodological distinction from ipamorelin. Preclinical data also indicate GHSR-independent cardioprotective effects at the cardiac level that persist in the absence of pituitary GH secretion.
Structure and receptor pharmacology
Hexarelin is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, sharing structural features with GHRP-6 and GHRP-2 but distinct in potency and receptor selectivity profile. The molecular formula is C₄₇H₅₈N₁₂O₆ (molecular weight 887.1 g/mol; CAS 140703-51-1). It was first described in the early 1990s as part of a systematic effort to optimize synthetic GHS potency and oral bioavailability.
Hexarelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a Gαq/11-coupled G protein-coupled receptor expressed in anterior pituitary somatotroph cells, hypothalamic nuclei, and peripheral tissues including the heart, adrenal glands, and liver. GHS-R1a activation initiates phospholipase C–mediated IP₃/DAG signaling, mobilizing intracellular calcium stores and driving exocytosis of pre-formed GH secretory granules.
In potency rankings from early pharmacology studies, hexarelin produced GH responses greater than those elicited by equivalent molar doses of GHRP-2, GHRP-6, or ipamorelin — placing it among the most potent synthetic GHRP compounds characterized in the published literature. Researchers comparing GHRP-6 and ipamorelin frequently reference this potency hierarchy when selecting compounds for specific research applications.
Cortisol and ACTH co-stimulation: the critical distinction from ipamorelin
The pharmacological feature that most clearly differentiates hexarelin from ipamorelin in research contexts is its co-stimulation of the hypothalamic-pituitary-adrenal (HPA) axis. Studies investigating hexarelin administration documented measurable elevations in cortisol and ACTH, a pattern not consistently observed at comparable doses of ipamorelin.
This distinction arises from receptor distribution: GHS-R1a is expressed not only on somatotroph cells but also on corticotroph and lactotroph cell populations in the anterior pituitary. Hexarelin's high binding affinity translates into partial stimulation of these populations, raising circulating cortisol and prolactin in parallel with GH. Ipamorelin, by contrast, demonstrates GH selectivity with negligible cortisol or prolactin stimulation at doses producing equivalent GH responses — a property attributed to its more restricted receptor engagement profile and pentapeptide structure.
For researchers designing GH axis studies, this distinction is methodologically important: protocols requiring isolated GH axis stimulation without adrenal confounding typically favor ipamorelin. Benchmark data from GHRP-2 stimulation testing (PMID 40277822) — which established average peak GH responses of 25.1 ng/mL in subjects with intact somatotroph function — illustrates the clinical diagnostic tradition of GHS-based pituitary stimulation, though that study used GHRP-2 rather than hexarelin. Hexarelin is selected in research contexts where maximal GH potency is the primary variable, or where HPA co-stimulation is not a confounding factor in the study design.
Published work in the ipamorelin GHRP research profile discusses the selectivity comparison in greater detail, including pharmacokinetic data on pentapeptide cortisol sparing.
Cardiac-specific, GHSR-independent signaling
A distinct body of hexarelin research investigates cardiac effects that appear to operate through pathways independent of pituitary GH release. Cardiac tissue expresses a hexarelin binding site pharmacologically distinct from the classical pituitary GHS-R1a — research has associated this activity with CD36-related scavenger receptor signaling or a structurally related cardiac GHS binding site.
Studies in rodent models, including work by Torsello and colleagues in the early 2000s, reported that hexarelin reduced cardiac fibrosis, attenuated ventricular diastolic dysfunction, and modulated cardiomyocyte survival signaling in aged rat hearts — effects that persisted in hypophysectomized animals where pituitary GH secretion was eliminated. This finding established a GH-independent mechanism operating at the cardiac level, distinct from hexarelin's pituitary effects.
Parallel cardioprotective findings in the GHRP-6 literature support the broader relevance of GHSR-adjacent cardiac signaling. A 2026 study (PMID 41901314) in a non-reperfusion myocardial infarction model demonstrated that GHRP-6 treatment attenuated left ventricular wall thinning, reduced myocardial interstitial fibrosis, and improved LV physiology post-surgery — with proteomic analysis pointing to upregulation of fatty acid beta-oxidation pathways, antioxidant defenses, and mitochondrial metabolic reprogramming as candidate mediators. Hexarelin's cardiac binding profile suggests mechanistic overlap, though compound-specific data should be interpreted on their own terms.
Researchers working with hexarelin or related GHRPs in cardiovascular models can cross-reference GHRP compound properties using the reconstitution calculator when preparing research-grade solutions.
WADA prohibition status
Hexarelin is classified on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which prohibits growth hormone secretagogues both in competition and out of competition. WADA's analytical strategy for hexarelin detection targets the intact parent compound and metabolite profiles generated through hepatic enzymatic cleavage.
A 2025 study (PMID 40465419) examined metabolite generation using pooled human hepatocyte incubations, with findings directly relevant to doping control methodology. The study investigated alexamorelin, a structural GHS precursor that undergoes hepatic C-terminal alanine cleavage via carboxypeptidase, yielding hexarelin (examorelin) as the primary detectable metabolite. The parent alexamorelin signal decreased approximately 150-fold within three hours of hepatocyte incubation, demonstrating rapid hepatic conversion. However, since hexarelin is itself a commercially available GHS compound and not unique to alexamorelin metabolism, it cannot serve as a definitive biomarker for alexamorelin-specific doping. Detection of the parent compound remains the gold standard.
This metabolic relationship has methodological implications for sports drug testing research and for laboratory purity characterization studies involving hexarelin. Researchers investigating GHRP-2 or GHRP-6 face analogous detection challenges given overlapping receptor pharmacology across the GHRP class.
Research context and regulatory status
Hexarelin is not approved by the FDA or EMA for any therapeutic indication. It has not been included on the FDA 503A Bulk Drug Substance Candidate List and is not available through licensed compounding pharmacies in the United States under current regulatory guidance. It is primarily accessible as a research-grade reference compound for in vitro and preclinical animal studies.
Its regulatory position differs from ipamorelin, which has maintained research-grade availability in some contexts, and from GHRP-6, which has an active preclinical literature focused on tissue protection and cardioprotection. Hexarelin's WADA prohibition status and absence from US compounding pathways represent the primary access constraints relevant to research planning.
Cited studies
- PMID 40465419 — "Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry" (2025). https://doi.org/10.1210/jcem.84.6.5815
- PMID 41901314 — "Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation" (2026). https://doi.org/10.1517/13543776.9.8.1075
- PMID 40277822 — "Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism" (2025). https://doi.org/10.1210/jcem.86.2.7214
Frequently asked questions
Q: What makes hexarelin more potent than ipamorelin for GH stimulation in research?
A: Hexarelin's hexapeptide structure achieves higher GHS-R1a receptor affinity than ipamorelin's pentapeptide framework in published potency comparisons, producing greater peak GH release per molar dose. This higher potency also drives co-stimulation of cortisol and ACTH pathways via corticotroph cell GHSR-1a engagement — a methodological trade-off not seen with ipamorelin.
Q: Does hexarelin's cortisol co-stimulation disqualify it for GH axis research protocols?
A: Not categorically. Cortisol co-stimulation is a methodological consideration, not an absolute disqualifier. Researchers studying GH axis biology in models where adrenal activity is independently monitored may select hexarelin precisely for its superior GH potency. Protocols requiring isolated GH axis stimulation without HPA confounding more typically use ipamorelin or GHRP-2 diagnostic stimulation designs.
Q: What is the cardiac hexarelin receptor and how does it differ from GHS-R1a?
A: Cardiac tissue expresses a hexarelin binding site pharmacologically distinct from the classical pituitary GHS-R1a — research has associated this with CD36 or a related scavenger receptor signaling pathway. Cardioprotective effects observed in hypophysectomized animals, where pituitary GH secretion is eliminated, indicate a GH-independent mechanism operating directly at the cardiac level, separate from hexarelin's pituitary activity.
Q: Is hexarelin available through compounding pharmacies in the United States?
A: Hexarelin has not been included on the FDA 503A Bulk Drug Substance Candidate List and is not available through licensed US compounding pharmacies under current regulatory guidance. Research-grade hexarelin is accessible as a reference compound for in vitro and preclinical animal studies only.
Q: Why does WADA prohibit hexarelin if it lacks FDA approval?
A: WADA's Prohibited List covers any GH secretagogue with the potential to elevate endogenous GH above physiological levels, regardless of regulatory approval status in any jurisdiction. Hexarelin's potent GHS-R1a agonism places it in Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which applies both in and out of competition. WADA detection methodology also covers the alexamorelin-to-hexarelin metabolic conversion pathway, as documented in the 2025 hepatocyte study (PMID 40465419).
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.